All it takes is a drop
A fingerstick-scale microsample (~5 µL) is mixed with assay-specific nanodetectors that respond to the biomarker of interest.
Bringing diagnostics beyond the lab.
Ilytica is developing an AI-enabled, image-based digital assay platform designed to bring lab-quality, quantitative biomarker testing directly to the patient, wherever they happen to be.
The Problem
Care is moving closer to the patient. Diagnostics still depend on the lab.
Telehealth and other decentralized care approaches have gone mainstream, yet most biomarker diagnostics remain confined to centralized labs. This creates a critical gap: 70% of clinical decisions require diagnostic input, but in decentralized settings that information is too often delayed, distant, or difficult to access.
Ilytica is developing a platform to solve this problem—allowing lab-quality biomarker diagnostic information to be available for any patient, wherever they are.
70%
of clinical decisions require diagnostic input.
The Technology
Ilytica gives AI a full picture of the assay
Current assay technology reduces the sample information into one bulk signal. That can work well in a controlled lab, but it becomes error-prone when testing moves into the real world. Ilytica reads the assay as a detailed image, using AI to separate biomarker signal from the errors, noise, and artifacts that make decentralized testing difficult.
Take a picture
The reader images thousands of individual assay events instead of reducing the sample to a single bulk signal.
AI error filtering
AI distinguishes the assay events from cells, debris, bubbles, focus changes, and other sources of noise.
Quantitative, lab-grade results
The AI system also converts that analysis into a quantitative, digital biomarker measurement and reports it to the user.
The Vision
Make diagnostics as simple as possible.
Collect a small sample, load it into a reader, and receive digital results in minutes.
The Proof
The peer-reviewed research behind the platform
Ilytica’s foundational publication in npj Imaging demonstrates homogeneous image-based digital immunoassays with high error tolerance.
5.2 ng/mL
reported detection limit
3.5 logs
reported dynamic range
30 min
reported mix-to-answer workflow
Whole blood
CRP proof-of-concept
The Team
A team built to rethink diagnostics
Ilytica brings together leadership and advisors with experience across assay science, molecular biophysics, machine learning, commercialization, strategy, and human-centered product development.
Will Rutter, MBA, MDes
CEO & Co-Founder
Strategy, product direction, partnerships, and company development.
Darren McAffee, PhD
CSO & Co-Founder
Scientific and technical development lead.
Jay T. Groves, PhD
Chief Scientific Advisor & Co-Founder
Platform inventor and development advisor.
Advisors include
Mickey Urdea, PhD
Bill Ferenczy
Ian Gonsher, MFA
Contact Ilytica